Analysts Set Adaptive Biotechnologies Corporation (NASDAQ:ADPT) PT at $20.83

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) has been given a consensus recommendation of “Moderate Buy” by the seven research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $23.3333.

Several research firms recently weighed in on ADPT. TD Cowen lifted their price target on shares of Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a “buy” rating in a report on Thursday. Morgan Stanley upped their price objective on shares of Adaptive Biotechnologies from $20.00 to $22.00 and gave the stock an “equal weight” rating in a report on Thursday. BTIG Research raised their target price on shares of Adaptive Biotechnologies from $24.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Friday, July 17th. Finally, JPMorgan Chase & Co. cut their target price on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th.

Adaptive Biotechnologies Price Performance

Shares of ADPT stock opened at $22.57 on Wednesday. The firm has a market cap of $3.61 billion, a P/E ratio of -55.05 and a beta of 2.08. Adaptive Biotechnologies has a fifty-two week low of $9.96 and a fifty-two week high of $24.57. The business’s 50 day moving average price is $19.43 and its 200-day moving average price is $16.65. The company has a debt-to-equity ratio of 2.22, a quick ratio of 4.68 and a current ratio of 4.79.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its earnings results on Tuesday, July 28th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.12). The business had revenue of $71.55 million for the quarter, compared to analysts’ expectations of $65.44 million. Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. Adaptive Biotechnologies’s quarterly revenue was up 21.5% on a year-over-year basis. During the same period last year, the firm posted ($0.17) earnings per share. On average, equities research analysts anticipate that Adaptive Biotechnologies will post -0.43 earnings per share for the current year.

Key Stories Impacting Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Adaptive raised its 2026 MRD revenue outlook to $268 million-$278 million and outlined plans to separate the MRD business. Management and analysts view the transaction as a potential way to create a focused, higher-growth “pure-play” company and unlock shareholder value. Adaptive outlines MRD separation plan while raising 2026 MRD revenue guidance
• Positive Sentiment: Second-quarter revenue was approximately $71.6 million, above the roughly $65.4 million consensus estimate and up 21.5% year over year. Zacks also reported an adjusted loss of $0.10 per share, narrower than the expected $0.13 loss and the $0.17 loss in the prior-year quarter. Adaptive Biotechnologies Reports Q2 Loss, Beats Revenue Estimates
• Positive Sentiment: Analysts raised their targets after the results: TD Cowen increased its target to $28 and maintained a Buy rating, while BTIG lifted its target to $25 and also retained a Buy rating. Analyst price-target coverage
• Neutral Sentiment: Zacks noted that ADPT’s 52-week-high performance reflects improving fundamentals, but investors must assess whether revenue growth, margins and the MRD separation can support additional appreciation. Adaptive Biotechnologies Hit a 52 Week High
• Negative Sentiment: Morgan Stanley raised its target only to $22 and kept an Equal Weight rating, implying limited upside at recent trading levels. The company remains unprofitable, and reported GAAP results included a larger-than-consensus quarterly loss, highlighting ongoing execution and profitability risks.

Insider Activity at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, insider Francis Lo sold 44,838 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $22.59, for a total transaction of $1,012,890.42. Following the transaction, the insider owned 230,713 shares in the company, valued at approximately $5,211,806.67. This represents a 16.27% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Susan Bobulsky sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $19.00, for a total value of $95,000.00. Following the transaction, the insider owned 411,775 shares in the company, valued at $7,823,725. This trade represents a 1.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 1,305,787 shares of company stock valued at $27,828,563. 5.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Adaptive Biotechnologies

Hedge funds have recently made changes to their positions in the company. Wasatch Advisors LP purchased a new stake in Adaptive Biotechnologies in the second quarter worth $12,361,000. Handelsbanken Fonder AB bought a new position in Adaptive Biotechnologies in the second quarter worth $1,416,000. Assenagon Asset Management S.A. purchased a new position in Adaptive Biotechnologies during the second quarter valued at $512,000. Perceptive Advisors LLC purchased a new position in Adaptive Biotechnologies during the first quarter valued at $2,117,000. Finally, Bank of America Corp DE boosted its holdings in shares of Adaptive Biotechnologies by 52.3% during the 1st quarter. Bank of America Corp DE now owns 1,227,917 shares of the company’s stock valued at $17,043,000 after buying an additional 421,645 shares in the last quarter. 99.17% of the stock is currently owned by institutional investors.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.